GlassScriptPhysician profile
Thomas G Triplett
NPI 1316203649
$5,604.00
in general payments reported to CMS, 2019-2025
28 companies · $916 in 2025
The $916 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $507 · 2021: $738 · 2022: $1,108 · 2023: $1,079 · 2024: $1,121 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,890 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.28 |
| Education | $225.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,115.23 | 2019-2024 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $743.75 | 2019-2025 | |
| Janssen Biotech, INC. | $694.88 | 2020-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $456.86 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $362.09 | 2020-2025 | Siliq, Jublia, Duobrii |
| Incyte Corporation | $298.73 | 2022-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $270.57 | 2023-2025 | Sotyktu |
| Pfizer INC. | $249.44 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $220.65 | 2020-2025 | Dupixent, Libtayo |
| Ucb, INC. | $158.88 | 2022-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $151.65 | 2020-2025 | |
| Galderma Laboratories, L.P. | $147.98 | 2021-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $125.05 | 2022-2023 | Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $109.41 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $81.29 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $65.61 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.57 | 2023 | Cyltezo, Spevigo |
| Organon LLC | $47.35 | 2025 | Nexplanon |
| Kyowa Kirin, INC. | $45.60 | 2023-2024 | Poteligeo |
| Arcutis Biotherapeutics, INC. | $37.15 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $33.15 | 2019-2020 | |
| Amgen INC. | $32.46 | 2023 | Otezla |
| Dermira, INC. | $25.18 | 2021 | |
| Botanix Sb INC | $19.69 | 2025 | Sofdra |
| Genentech USA, INC. | $19.04 | 2020 | |
| Cipher Pharmaceuticals US LLC | $18.13 | 2025 | Spinosad, Natroba |
| Epi Health, LLC | $15.44 | 2021 | |
| Merck Sharp & Dohme LLC | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Triplett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.